RepliCel’s latest update on RCH-01.
For those who are new to our community: RCH-01 is a cell based hair restoration procedure using dermal sheath cup (DSC) cells harvested from the patient’s donor follicles, usually from the back of the patient’s scalp. The harvested cells will then be multiplied and injected into the balding areas of the patient’s scalp. If successful, this treatment could potentially eliminate the need for invasive hair transplant surgery.
Below are excerpts from RepliCel’s 2017 forecast which some of you may find interesting:
In 2012, when we announced the safety and 6-month clinical efficacy data from our phase 1 study of RCH-01 (pattern baldness), we knew that in 2017 we would have 5-year safety data and both 12 and 24-month efficacy data which was all locked until the completion of the 5-year trial (all the trial participant data needed for this announcement has been collected and is now being prepared for third-party analysis)
In Japan, we are pleased Shiseido continues to fund the two-site clinical research study for pattern baldness (RCH-01)… We look forward to data from the Japanese RCH-01 (pattern baldness) study anticipated sometime in 2018 and continue to develop our own plans around the asset for markets outside Asia.
You can read the full forecast on their website at http://replicel.com/replicel-ceo-provides-2017-forecast/